Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients
Sponsor: Mundipharma K.K.
This PHASE1/PHASE2 trial investigates Recurrent or Refractory PTCL and is currently completed. Mundipharma K.K. leads this study, which shows 8 recorded versions since 2013 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
▶ Show 3 earlier versions
-
Jun 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
Status: Unknown Status → Completed
-
Feb 2017 — Jun 2017 [monthly]
Unknown Status PHASE1_PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1_PHASE2
First recorded
Jan 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Mundipharma K.K.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Akashi, Japan , Chūō, Japan , Fukui, Japan , Fukuoka, Japan , Isehara, Japan , Izumo, Japan , Kagoshima, Japan , Kashiwa, Japan , Koto, Japan , Kumamoto, Japan and 9 more locations